Literature DB >> 32401687

Severe suppurative otitis media due to Streptococcus pneumoniae serotype 19A in a fully vaccinated infant by age.

Saliha Kanik-Yuksek1, Belgin Gülhan1, Aslınur Özkaya-Parlakay1, Tuğba Bedir Demirdağ1.   

Abstract

The routine use of pneumococcal conjugated vaccines (PCVs) in childhood has significantly reduced the frequency of invasive pneumococcal diseases (IPDs). Serotype replacement has occurred, resulting in an increase in nonvaccine serotypes. Despite this changing profile, both invasive and noninvasive cases continue to be seen with strains within the scope of PCV coverage. Although older children with comorbid disease are described as a risky group for vaccine insufficiency, vaccine failure patterns should be described in detail.

Entities:  

Keywords:  S.pneumoniae; conjugated pneumococcal vaccine; pneumococcal disease; serotype 19A

Year:  2020        PMID: 32401687      PMCID: PMC7746249          DOI: 10.1080/21645515.2020.1747924

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  5 in total

Review 1.  Pathogenesis of pneumococcal infection.

Authors:  S H Gillespie; I Balakrishnan
Journal:  J Med Microbiol       Date:  2000-12       Impact factor: 2.472

2.  Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016.

Authors:  Tolulope A Adebanjo; Tracy Pondo; David Yankey; Holly A Hill; Ryan Gierke; Mirasol Apostol; Meghan Barnes; Susan Petit; Monica Farley; Lee H Harrison; Corinne Holtzman; Joan Baumbach; Nancy Bennett; Suzanne McGuire; Ann Thomas; William Schaffner; Bernard Beall; Cynthia G Whitney; Tamara Pilishvili
Journal:  Pediatrics       Date:  2020-02-13       Impact factor: 7.124

Review 3.  Pneumococcal conjugate vaccine failure in children: A systematic review of the literature.

Authors:  Godwin Oligbu; Yingfen Hsia; Laura Folgori; Sarah Collins; Shamez Ladhani
Journal:  Vaccine       Date:  2016-11-09       Impact factor: 3.641

4.  Pneumococcal pneumonia vaccine breakthroughs and failures after 13-valent pneumococcal conjugated vaccine.

Authors:  Ana Filipe Almeida; Joana Sobrinho-Simões; Catarina Ferraz; Teresa Nunes; Luisa Vaz
Journal:  Eur J Public Health       Date:  2016-06-21       Impact factor: 3.367

5.  Who is at risk of 13-valent conjugated pneumococcal vaccine failure?

Authors:  Melike Yildirim; Pinar Keskinocak; Stephen Pelton; Larry Pickering; Inci Yildirim
Journal:  Vaccine       Date:  2020-01-20       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.